4 October 2024 in Pain Practice
Introduction: Patients suffering from postherpetic neuralgia (PHN) report unilateral chronic pain in one or more dermatomes after an acute herpes zoster (HZ) infection. The incidence of acute HZ ranges between three and five patients per 1000 person‐years. In one out of four patients, acute HZ‐related pain will transition into PHN. PHN can be very disabling for patients and reduce quality of life. Additionally, the treatment of PHN is characterized by high failure rates. The aim of this review is to give an update on the previous practical guideline published in 2011 and revised in 2015 (published in 2019) and to provide an overview of current interventional treatment options for HZ infection and PHN.Methods: The literature on the diagnosis and treatment of HZ and PHN was systematically reviewed and summarized.Results: The most important treatment for acute HZ‐related pain is antiviral therapy within 72 h of symptom onset. Additional symptomatic treatment options are analgesic drugs according to the WHO pain ladder, tricyclic antidepressants (eg, nortriptyline), and antiepileptic drugs (eg, gabapentin). If pain is not sufficiently reduced, interventional treatment such as an epidural injection with local anesthetics and corticosteroids or pulsed radiofrequency of the dorsal root ganglion (DRG) are options. Treatment for PHN is preferably transdermal capsaicin, lidocaine, or oral drugs such as antidepressants or antiepileptics.Conclusions: Treatment of acute HZ‐related pain especially PHN is challenging. Besides the conventional treatment for PHN, interventional management is considered a new treatment option. PRF of DRG seems to be the most promising interventional management.
4 March 2025 in Pain Practice
29 April 2026 in Pain Reports
Introduction: Herpes zoster (HZ) predominantly affects sensory nerves and can lead to postherpetic neuralgia. A motor deficit in the corresponding myotome is a rare but severe complication. Objectives: The objective of this study was to further characterize patients with HZ-related motor deficits and to explore potential risk factors. Methods: This retrospective cohort study in the tertiary pain clinic of the University Medical Center Utrecht, includes a comparative analysis of patients presenting with and without motor deficit resulting from HZ. Patient characteristics including psychological distress were assessed using standardized questionnaires, and Quantitative Sensory Testing outcomes were analysed between the 2 groups. Results: The study population included 158 patients with postherpetic neuralgia, of whom 17 patients had motor paralysis. In the motor paralysis group, most were male (94.1%). The median pain intensity was NRS 7, similar in both groups. Anxiety, depression, Pain Catastrophizing Scale, and DN4 scores did not differ significantly between groups. Tampa Scale of Kinesiophobia, indicating kinesiophobia did significantly differ between both groups ( P = 0.043). Patients with motor deficit showed distinct sensory profiles characterized by sensory loss in 70.6% of patients compared with 35.5% in the group without motor deficit ( P = 0.017). Conclusion: Motor deficit may be more common than we realize and is a serious complication of HZ. Patients who experienced motor deficit as a complication of herpes zoster demonstrated more severe nerve damage, with sensory loss being the most frequent sensory phenotype. More awareness is needed for this serious complication accompanied with research guiding treatment and rehabilitation protocols.
12 December 2025 in Pain Practice